RARA
Retinoic acid receptor alpha
As of the edition of 20 October 2026, RARA (retinoic acid receptor alpha, UniProt P10276) has 11 drugs tested at it and 21 companies on the list, 0 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10276
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 14
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive; Infections; Lungs and airways; Digestive system
- Registered trials of its drugs
- 429
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tretinoin | Marketed | Phase 4 | none listed |
| Isotretinoin | Marketed | Phase 4 | none listed |
| Adapalene | Marketed | Phase 4 | none listed |
| Tazarotene | Marketed | Phase 4 | none listed |
| Acitretin | Marketed | Phase 4 | none listed |
| Alitretinoin | Marketed | Phase 3 | none listed |
| Tamibarotene | Stopped | Phase 3 | none listed |
| NRX195183 | Stopped | Phase 2 | none listed |
| TMB-001 | Status not established | Phase 3 | none listed |
| YCT-529 | Active | Phase 2 | none listed |
| Etretinate | Withdrawn from market | No phase stated | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 6 |
| Engaged | 7 |
| Undetermined | 8 |
| Total on the list | 21 |
The other 18 companies at RARA
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at RARA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.